Journal: ACS Omega

Article Title: Development of an Analytical Method for Determination of Related Substances and Degradation Products of Cabotegravir Using Analytical Quality by Design Principles

doi: 10.1021/acsomega.1c07260

Figure Lengend Snippet: Chromatogram of cabotegravir and its related substances ( 2CBG , 4CBG , dFCBG , and HICBG ) as well as its degradation products ( DP1 , DP2 , DP3 , DP4 ) analyzed with initial chromatographic conditions (MP A: 0.5% formic acid:ACN (94:6, v/v); MP B: MeOH:ACN (94:6, v/v); Acquity UPLC BEH Phenyl column, 1.7 μm, 150 mm × 2.1 mm; T c = 35 °C; flow rate = 0.3 mL/min. Gradient: t = 0 min, 42% B; 18 min, 42% B; 20 min, 59% B; 22 min, 89% B; 29 min, 89% B; 29,5 min, 42% B; 5.5 min equilibration).

Article Snippet: Cabotegravir, chemically known as (3 S ,11 aR )- N -((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11 a -hexahydrooxazolo(3,2- a )pyrido(1,2- d )pyrazine-8-carboxamide ( Figure ) is a second-generation integrase inhibitor, developed by Viiv Healthcare for HIV treatment and pre-exposure prophylaxis.

Techniques:

Journal: ACS Omega

Article Title: Development of an Analytical Method for Determination of Related Substances and Degradation Products of Cabotegravir Using Analytical Quality by Design Principles

doi: 10.1021/acsomega.1c07260

Figure Lengend Snippet: Chromatogram of the best chromatographic conditions for separation of cabotegravir, its eight impurities, and one unknown impurity from method scouting. Chromatographic conditions: MP A, phosphate buffer, pH = 2.0; MP B, ACN; Acquity UPLC BEH Phenyl column, 1.7 μm, 150 mm × 2.1 mm; T c = 40 °C; flow rate = 0.3 mL/min. Gradient: t = 0 min, 30% B; 1 min, 30% B; 16 min, 90% B; 17 min, 30% B; 3 min equilibration.

Article Snippet: Cabotegravir, chemically known as (3 S ,11 aR )- N -((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11 a -hexahydrooxazolo(3,2- a )pyrido(1,2- d )pyrazine-8-carboxamide ( Figure ) is a second-generation integrase inhibitor, developed by Viiv Healthcare for HIV treatment and pre-exposure prophylaxis.

Techniques:

Journal: ACS Omega

Article Title: Development of an Analytical Method for Determination of Related Substances and Degradation Products of Cabotegravir Using Analytical Quality by Design Principles

doi: 10.1021/acsomega.1c07260

Figure Lengend Snippet: Trellis graphs from DoE study to establish CMA models and robustness testing. Graph is showing by white color an area where defined criteria are met, the design space. Other colors represent areas where the criteria are not met: dark blue = R DP4 , HICBG ≤ 2.0, purple = C pk ( R DP4 , HICBG ) ≤ 1.33; light blue = R 2CBG , 4CBG ≤ 2.0, orange = C pk ( R 2CBG , 4CBG ) ≤ 1.33; pink = R 4CBG , cabotegravir ≤ 2.0, lime = C pk ( R 4CBG , cabotegravir ) ≤ 1.33, x = pump flow rate (0.2–0.4 mL/min); y = final percent of acetonitrile in gradient (50–90%) at pH of 2.75 (top line), 3.25 (middle line), and 3.75 (bottom line); and column temperature of 30 (left column), 40 (middle column), and 50 °C (right column).

Article Snippet: Cabotegravir, chemically known as (3 S ,11 aR )- N -((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11 a -hexahydrooxazolo(3,2- a )pyrido(1,2- d )pyrazine-8-carboxamide ( Figure ) is a second-generation integrase inhibitor, developed by Viiv Healthcare for HIV treatment and pre-exposure prophylaxis.

Techniques:

Journal: ACS Omega

Article Title: Development of an Analytical Method for Determination of Related Substances and Degradation Products of Cabotegravir Using Analytical Quality by Design Principles

doi: 10.1021/acsomega.1c07260

Figure Lengend Snippet: Detection Limit Results from Analytical Method Validation

Article Snippet: Cabotegravir, chemically known as (3 S ,11 aR )- N -((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11 a -hexahydrooxazolo(3,2- a )pyrido(1,2- d )pyrazine-8-carboxamide ( Figure ) is a second-generation integrase inhibitor, developed by Viiv Healthcare for HIV treatment and pre-exposure prophylaxis.

Techniques:

Journal: ACS Omega

Article Title: Development of an Analytical Method for Determination of Related Substances and Degradation Products of Cabotegravir Using Analytical Quality by Design Principles

doi: 10.1021/acsomega.1c07260

Figure Lengend Snippet: Quantification Limit Results from Analytical Method Validation

Article Snippet: Cabotegravir, chemically known as (3 S ,11 aR )- N -((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11 a -hexahydrooxazolo(3,2- a )pyrido(1,2- d )pyrazine-8-carboxamide ( Figure ) is a second-generation integrase inhibitor, developed by Viiv Healthcare for HIV treatment and pre-exposure prophylaxis.

Techniques:

Journal: ACS Omega

Article Title: Development of an Analytical Method for Determination of Related Substances and Degradation Products of Cabotegravir Using Analytical Quality by Design Principles

doi: 10.1021/acsomega.1c07260

Figure Lengend Snippet: Linearity Results for Cabotegravir and All Eight Impurities from Analytical Method Validation

Article Snippet: Cabotegravir, chemically known as (3 S ,11 aR )- N -((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11 a -hexahydrooxazolo(3,2- a )pyrido(1,2- d )pyrazine-8-carboxamide ( Figure ) is a second-generation integrase inhibitor, developed by Viiv Healthcare for HIV treatment and pre-exposure prophylaxis.

Techniques:

Journal: eLife

Article Title: Targeting RNA:protein interactions with an integrative approach leads to the identification of potent YBX1 inhibitors

doi: 10.7554/eLife.80387

Figure Lengend Snippet: Supplier list and compound IDs of the 40 tested molecules.

Article Snippet: D4 , Cabotegravir , MolPort-035-944-338 , MolPort.

Techniques: